isolated and washed with mother liquor, then with water until
filtrate pH is neutral, dried at room temperature to constant
weight. Obtained, 10d (2.2 g, 65.3%). HPLC purity was 100%.
IR (KBr) cm−1 m 3132, 3066, 1595, 1495, 1472, 1446, 1375, 1236,
structures in this article. We also thank our colleagues, Henry
Cheng, David Koss, Jin Li, and Subas Sakya, who independently
observed the same un-dehydrated intermediate 9a and provided
useful discussion on the topic of this work.
1
1154, 1136; H NMR (400 MHz, CDCl3) d 6.76 (s, 5 H), 7.25
(m, 5 H); 13C NMR (CDCl3) d 129.6, 129.4, 129.4, 129.2, 129.1,
129.0, 128.9, 128.7, 126.1, 126.0, 125.7, 105.8; HRMS m/z (M+)
C16H11F3N2H+required 289.0952, obsd 289.0950.
References
1 M. J. Genin, C. Biles, B. J. Keiser, S. M. Poppe, S. M. Swaney, W. G.
Tarpley, Y. Yagi and D. L. Romero, J. Med. Chem., 2000, 43, 1034.
2 A. Guzman-Perez, R. T. Webster, M. C. Allen, J. A. Brown, A. R.
Buchholz, E. R. Cook, W. W. Day, E. S. Hamanaka, S. P. Kennedy,
D. R. Knight, P. J. Kowalczyk, R. B. Marala, C. J. Mularski, W. A.
Novomisle, R. B. Ruggeri, W. R. Tracy and R. J. Hill, Bioorg. Med.
Chem. Lett., 2001, 11(6), 803.
3-(Difluoromethyl)-1,5-diphenyl-1H-pyrazole (10e)
Ketone 5b, 1.5 g (7.6 mmol, 0.96 equiv.), hydrazine 4b, 800 lL
(7.9 mmol, 1.04 equiv.), and 2-propanol (45 ml) were stirred
for 30 min at 30 ◦C, added conc. H2SO4 43 ll (0.8 mmol, 0.1
equiv.) heated at 83 ◦C for 60 min. The reaction mixture was
cooled <45 ◦C and water (50 ml) added, extracted with ethyl
acetate (3 × 20 ml). The combined organic phase was dried over
Na2SO4. Concentrated to obtain 10e (2.01 g, 98%). HPLC purity
was 92%; 97/3 regio-isomer ratio. 1H NMR (300 MHz, CDCl3)
d 6.77 (dd, 1 H, J = 20.53, 54.95 Hz), 7.28–7.38 (m, 10 H);
13C NMR (CDCl3) d 139.7, 129.9, 129.3, 129.3, 129.0, 129.0,
128.9, 128.8, 128.4, 125.6, 113.9 (CHF2), 111.6 (CHF2), 109.3
(CHF2), 105.0; HRMS m/z (M+) C16H12F2N2H+ 271.1047, obsd
271.1048.
3 T. D. Penning, J. J. Talley, S. R. Bertenshaw, J. S. Carter and P. W.
Collins, J. Med. Chem., 1997, 40, 1347.
4 J. Li, K. M. L. DeMello, H. Cheng, S. M. Sakya, B. S. Bronk, R. J.
Rafka, B. H. Jaynes, C. B. Ziegler, C. Kilroy, D. W. Mann, E. L.
Nimz, M. P. Lynch, M. L. Haven, N. L. Kolosko, M. L. Minich, C.
Li, J. K. Dutra, B. Rast, R. M. Crosson, B. J. Morton, G. W. Kirk,
K. M. Callaghan, D. A. Koss, A. Shavnya, L. A. Lund, S. B. Seibel,
C. F. Petras and A. Silvia, Bioorg. Med. Chem. Lett., 2004, 14, 95.
5 K. von Auwers and W. Schmidt, Chem. Ber., 1925, 58, 528.
6 K. N. Zetenin, V. V. Alekseyev, A. R. Tygysheva and S. I. Yaki-
movitch, Tetrahedron, 1995, 51(41), 11251.
7 (10f) is prepared as the exclusive (>99%) pyrazole isomer by con-
densing phenylhydrazine (4b) with benzoylacetone (5c) in ethanol–
water 2 : 1 in the presence of sodium acetate at reflux, see reference
3, page 1036. This compound has been used to prepare other 1,5-
diphenylpyrazoles that have known regio-isomerism.
5-(Methylsulfonyl)-2-[3-phenyl-5-(trifluoromethyl)-pyrazol-1-
yl]pyridine (11a)
8 Main and minor products were estimated by normalized chro-
matograms using authentic reference samples to confirm correct
identification by retention time. Column; Kromasil C8. 5 mm
spherical particles 150 mm × 4.6 mm, mobile phase; 55% 20 mM
potassium phosphate buffer, pH 3.0, 45% acetonitrile, flow rate;
1.0 mL g−1, injection vol., 10 lL wavelength of detection; 250 nm,
temperature; 35 ◦C, instrument; HP 1100 series.
9 S. P. Singh, D. Kumar, H. Batra, R. Nathani, I. Rozas and Jose
Elguero, Can. J. Chem., 2000, 78, 1109.
10 J. Elguero and G. I. Yranzo, J. Chem. Res. Synop., 1990, 120.
11 Single crystal X-ray data. Compound 8b: C16H15N3O3SF2; (M),
Pyrazoline 9a 130 mg (0.34 mmol, 1.0 equiv.), 2-propanol (20 ml)
and conc. H2SO4 72 ll (0.8 mmol, 1.5 equiv.) were heated at
83 ◦C for 24 h. A second portion of conc. H2SO4 was added
(57 lL, 1.0 mmol, 3.0 equiv.) and heating continued for 48 h. The
reaction mixture was cooled and stirred at ambient temperature
for 1 h. Isolated precipitated solid, washed with water until
neutral pH filtrate was obtained, dried at room temperature
1
to constant weight. Obtained pyrazole 11a (104 mg, 83%). H
NMR (400 MHz, CDCl3) d 9.03 (d, 1 H, J = 2.5 Hz), 8.27
(dd, 1 H, J = 8.7, 60.6 Hz), 7.73 (m, 1 H, 3 H), 7.42–7.52 (m,
5 H), 7.26 (s, 1 H), 3.2 (s, 3 H); 13C (100 MHz, d6-DMSO) d
153.7, 153.1, 147.8, 139.6, 136.6, 133.5 (q, J = 40.8 Hz), 130.9,
130.2, 129.6, 127.3, 126.6, 116.3, 111.8, 44.3; HRMS m/z (M+)
C16H12F3N3O2SH+ found: 368.0680, calc: 368.0681
367.37; unit cell dimensions (A, ◦) a = 10.5772(4), b = 17.2951(7),
˚
3
˚
c = 9.3940(4), a = 90, b = 109.7810(10), c = 90; vol. 1617.08(11) A ;
space group, P2(1)/c; (Z), 4; (l), 2.188 mm−1; independent reflections
1285[R(int) = 0.1021]; final R indices [I > 2r(I)], R1 = 0.0505,
wR2 = 0.1276. Compound 8c: C16H17N3O3S; (M), 331.39; unit cell
dimensions (A, ◦) a = 15.9809(10), b = 9.4557(6), c = 10.5313(7),
˚
3
˚
a = 90, b = 90.4710(10), c = 90; vol. 1591.34(18) A ; space
group, P2(1)/c; (Z), 4; (l), 0.222 mm−1; independent reflections
1663 [R(int) = 0.0592]; final R indices [I > 2r(I)], R1 = 0.0370,
wR2 = 0.0928. Compound 9a: C16H14F3N3O3S; (M), 385.36; unit cell
2-(5-Difluoromethyl-3-phenylpyrazol-1-yl)-5-methanesulfonyl-
pyridine (11b)
dimensions (A, ◦) a = 8.3741(5), b = 19.8459(13), c = 10.4665(7),
˚
The source of 11b was from a mixture of previous mother liquors
obtained from the synthesis of 10b. 11b was purified by column
chromatography using silica gel as stationary phase (Biotage
System, 75 L) and dichloromethane as the mobile phase. This
separation yielded 11b (3.5 g). HPLC purity of 99.0%. 1H NMR
(400 MHz, CDCl3) 8.97 (d, 1 H, J = 1.7 Hz), 8.15 (dd, 1 H, J =
2.1, 6.6 Hz), 7.9 (d, J = 6.64 Hz, 1 H) 7.76 (t, 1 H, J = 54.8 Hz),
7.46 (m, 3 H), 7.19 (s, 1 H), 3.15 (s, 1 H); 13C NMR (CDCl3) d
147.88, 138.48, 134.47, 129.62, 129.15, 126.37, 114.57, 109.13,
108.32, 45.31; Anal. Cald. for C16H13F2N3O2S: C, 55.01; H, 3.75;
F, 10.88; N, 12.03; O, 9.16; S, 9.18. Found: C, 54.97; H, 3.58; F,
10.83; N, 11.90; S, 9.34%. HRMS m/z (M+) C16H13F2N3O2SH+
requires 350.0775, obsd. 350.0779.
3
˚
a = 90, b = 108.8450(10), c = 90; vol. 1646.20(18) A ; space
group, P2(1)/n; (Z), 4; (l), 0.252 mm−1; independent reflections
1721[R(int) = 0.0542]; final R indices [I > 2r(I)], R1 = 0.0295, wR2 =
0.0767. Compound 10a: C16H12F3N3O3S; (M), 367.35; unit cell
dimensions (A, ◦) a = 31.208(4), b = 5.0510(10), c = 21.756(2), a =
˚
3
˚
90, b = 110.080(10), c = 90; vol. 3221.0(8) A ; space group, C2/c; (Z),
8; (l), 2.245 mm−1; independent reflections 1639 [R(int) = 0.0130];
final R indices [I > 2r(I)], R1 = 0.0445, wR2 = 0.1021. Compound
10b: C16H13F2N3O2S; (M), 349.35; unit cell dimensions (A, ◦) a =
˚
10.614(2), b = 7.4840(10), c = 20.523(3), a = 90, b = 96.250(10), c =
3
−1
˚
90; vol. 1620.6(4) A ; space group, P2(1)/c; (Z), 4; (l), 2.108 mm
;
independent reflections 1674 [R(int) = 0.0181]; final R indices
[I>2r(I)], R1 = 0.0419, wR2 = 0.1017. Compound 10d: C16H11F3N2;
◦
˚
(M), 288.27; unit cell dimensions (A, ) a = 8.4600(10), b = 16.282(2),
c = 10.7060(10), a = 90, b = 107.520(10), c = 90; vol. 1406.3(3)
3
A ; space group, P2(1)/n; (Z), 4; (l), 0.935 mm−1; independent
˚
Acknowledgements
reflections 1449 [R(int) = 0.0306]; final R indices [I > 2r(I)], R1 =
0.0461, wR2 = 0.1104. CCDC reference numbers 263085–263090.
See http://www.rsc.org/suppdata/ob/b5/b500413f/ for crystallo-
graphic data in CIF or other electronic format.
The authors thank colleagues Michael J. Castaldi and Dennis
E. Bourassa for invaluable experimental assistance, Professor
Steven Ley (Cambridge) for helpful discussions and Jon Bordner
and Ivan Samardjiev for solving the single crystal X-ray
12 D. E. Bourassa, M. J. Castaldi and D. H. B. Ripin, US Patent
6646128, 11 November 2003.
O r g . B i o m o l . C h e m . , 2 0 0 5 , 3 , 1 8 4 4 – 1 8 4 9
1 8 4 9